Memorial Sloan Kettering Cancer Center

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Memorial Sloan Kettering Cancer Center sits in the top decile of US sponsors by registered trial count (#6 of 15,751 sponsors by registered trial count).

1,884 total trials 327 currently recruiting 1104 completed early-phase tilt top decile by trial count

Memorial Sloan Kettering Cancer Center: 1,884 sponsored US clinical trials, 327 recruiting.

Memorial Sloan Kettering Cancer Center sponsors 1,884 registered US clinical trials on ClinicalTrials.gov, 327 of them currently recruiting, and 1,104 completed. 75 of these trials are in Phase 3-4 (later-stage) and 1,101 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 98 trials.

Top-decile sponsor footprint

Memorial Sloan Kettering Cancer Center ranks in the top decile of sponsors by registered trial count (#6 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

1,884 total, page 32 of 38

COMPLETED

Research on the Environment and Children's Health: Retinoblastoma

NCT00582049

COMPLETED Phase 2

Amonafide in Treating Women With Metastatic Breast Cancer That Has Progressed After Previous Chemotherapy

NCT00074100

COMPLETED

Quality Of Life Outcomes Following Treatment for Esophageal Cancer

NCT00598117

COMPLETED Phase 2

Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer

NCT00072319

COMPLETED Phase 1

Edotecarin and Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors

NCT00072332

COMPLETED Phase 2

Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma

NCT00072358

COMPLETED Phase 2

Phase II Study of Chemotherapy and Pamidronate for the Treatment of Newly Diagnosed Osteosarcoma

NCT00586846

COMPLETED

Use of Screening Colonoscopy Among Minority Women and Men

NCT00613873

COMPLETED Phase 2

Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma

NCT00072345

COMPLETED Phase 2

Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer

NCT00587431

COMPLETED Phase 2

Edotecarin in Treating Women With Locally Advanced or Metastatic Breast Cancer That Has Not Responded to Chemotherapy

NCT00070031

COMPLETED

Colorectal Cancer Screening Intervention for Family Members of Colorectal Cancer Patients

NCT00582829

COMPLETED Phase 2

A Phase II Study of Continuous Hepatic Arterial Infusion With Floxuridine (FUDR) and Dexamethasone (DEX) in Patients With Unresectable Primary Hepatic Malignancy

NCT00587067

COMPLETED NA

Imaging Brain Tumors With FACBC and Methionine

NCT00597246

COMPLETED NA

Breast MRI Spectroscopy

NCT00577915

COMPLETED

Adherence to Intensive Surveillance for Hereditary Breast Cancer

NCT00582803

COMPLETED Phase 3

Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer

NCT00067015

COMPLETED Phase 2

Massage Therapy in Treating Patients With Cancer Pain

NCT00082290

COMPLETED Phase 3

A Prospective Randomized Trial of Pre-Operative IMRT+Surgery Versus Surgery Alone For Primary Retroperitoneal Sarcoma

NCT00131898

COMPLETED Phase 1

Irinotecan, Radiation Therapy, and Docetaxel With or Without Cisplatin in Treating Patients With Locally Advanced Esophageal Cancer

NCT00601692

COMPLETED

3-D Reconstruction of CT Scan Images in the Evaluation of Non-Specific Pulmonary Nodules

NCT00613041

COMPLETED

Decision-making Regarding Prophylactic Mastectomy and Oophorectomy in Women Seeking Genetic Counseling and Testing for BRCA1/2 Mutations

NCT00579007

COMPLETED Phase 2

Alanosine in Treating Patients With Cancer

NCT00062283

COMPLETED

DNA Repair and Genetic Susceptibility to Lung Cancer

NCT00611598

COMPLETED Phase 2

Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma

NCT00058422

COMPLETED NA

Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma

NCT00058370

COMPLETED

Evaluation of Enrollment, Dynamics of Care and Patient Outcomes in the NYS Medicaid HIV Special Needs Plans

NCT00577811

COMPLETED NA

Intra-Operative Lymphatic Mapping in Patients With Invasive Carcinoma of the Cervix or Endometrial Carcinoma

NCT00595725

COMPLETED

Prospective Study of Possible Infectious Disease - Associated Antigen Drive in Previously Untreated Indolent Lymphoma

NCT00582270

COMPLETED

The Role of Genetic Polymorphisms in Innate Immune Response Genes in Susceptibility to Infections

NCT00597090

COMPLETED

Family Access to Care Study (FACS)

NCT00582218

COMPLETED Phase 3

Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma

NCT00142571

COMPLETED Phase 2

Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma

NCT00059904

COMPLETED Phase 1

PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer

NCT00055705

COMPLETED Phase 1

Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer

NCT00059930

COMPLETED Phase 1

Polyglutamate Camptothecin in Treating Patients With Advanced Cancer

NCT00059917

COMPLETED Phase 1

MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma

NCT00059995

COMPLETED Phase 1

Vaccine Therapy of Prostate Cancer Patients With Recombinant Soluble Prostate-Specific Membrane Antigen (Rs-PSMA) Plus the Immunological Adjuvant Alhydrogel

NCT00705835

COMPLETED NA

Anal Sphincter Prosthesis in Treating Patients Who Are Undergoing Surgery for Anal or Rectal Cancer

NCT00059891

COMPLETED

Methylated Genes in Blood as Biomarkers for Advanced Lung Cancer

NCT00579462

COMPLETED Phase 1

Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer

NCT00058435

COMPLETED Phase 3

Outcome of Palliative Management of Malignant Large Bowel Obstruction w/Colorectal Stents or Surgery

NCT00140868

COMPLETED Phase 2

Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.

NCT00590031

COMPLETED NA

Improving Therapeutic Outcomes in the Tongue Carcinoma Patient: Assessment of Adaptation Using Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging

NCT00594724

COMPLETED Phase 2

Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders

NCT00052572

COMPLETED Phase 2

Doxorubicin and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Soft Tissue Sarcoma

NCT00052390

COMPLETED Phase 2

Psychostimulants for Fatigue in Prostate Cancer

NCT00138138

COMPLETED NA

Quadrant High Dose Rate Intraoperative Radiation Therapy (IORT) for Early-Stage Breast Cancer: A Pilot Study

NCT00595062

COMPLETED Phase 2

SHO-SAIKO-TO for Patients With Chronic Hepatitis C: A Phase II Study

NCT00590564

COMPLETED Phase 1

Monoclonal Antibody in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT00058396

← Previous Page 32 of 38 Next →

Phase Distribution

PhaseTrial count
Phase 1 461
Phase 2 640
Phase 3 67
Phase 4 8

What is open in the Memorial Sloan Kettering Cancer Center pipeline

327 recruiting of 1,884 indexed (17% open); 1,104 completed (59%).

Phase mix: 75 late (III/IV) vs 1,101 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (98 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.